Price Change to Note: Insulet Corporation on Focus After Crashing In Today’s Session

Price Change to Note: Insulet Corporation on Focus After Crashing In Today's Session

The stock of Insulet Corporation (NASDAQ:PODD) is a huge mover today! About 176,884 shares traded hands. Insulet Corporation (NASDAQ:PODD) has risen 29.97% since March 8, 2016 and is uptrending. It has outperformed by 20.65% the S&P500.
The move comes after 9 months negative chart setup for the $2.27B company. It was reported on Oct, 11 by We have $36.44 PT which if reached, will make NASDAQ:PODD worth $136.20 million less.

Analysts await Insulet Corporation (NASDAQ:PODD) to report earnings on November, 3. They expect $-0.07 EPS, up 78.79% or $0.26 from last year’s $-0.33 per share. After $-0.08 actual EPS reported by Insulet Corporation for the previous quarter, Wall Street now forecasts -12.50% EPS growth.

Insulet Corporation (NASDAQ:PODD) Ratings Coverage

Out of 9 analysts covering Insulet Corporation (NASDAQ:PODD), 5 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 56% are positive. Insulet Corporation has been the topic of 17 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm earned “Equal-Weight” rating on Monday, November 2 by Morgan Stanley. The company was initiated on Thursday, February 25 by Empire. Benchmark upgraded it to “Buy” rating and $40 target price in Friday, February 26 report. The firm has “Hold” rating given on Thursday, August 13 by Benchmark. The firm earned “Outperform” rating on Friday, November 6 by Northland Capital. Jefferies maintained the stock with “Buy” rating in Thursday, August 4 report. The firm has “Outperform” rating by William Blair given on Friday, April 29.

According to Zacks Investment Research, “INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company’s OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes.”

Insitutional Activity: The institutional sentiment increased to 1.35 in Q2 2016. Its up 0.43, from 0.92 in 2016Q1. The ratio is positive, as 18 funds sold all Insulet Corporation shares owned while 45 reduced positions. 29 funds bought stakes while 56 increased positions. They now own 59.20 million shares or 0.11% less from 59.26 million shares in 2016Q1.
Pacad Ltd, a British Columbia – Canada-based fund reported 26,823 shares. Segall Bryant & Hamill Limited Liability owns 257,731 shares or 0.21% of their US portfolio. The Massachusetts-based Panagora Asset Management has invested 0% in Insulet Corporation (NASDAQ:PODD). Blackrock Advsr Lc accumulated 366,051 shares or 0.01% of the stock. Franklin Resources holds 0.01% of its portfolio in Insulet Corporation (NASDAQ:PODD) for 449,469 shares. Jennison Assocs Lc accumulated 0% or 15,122 shares. Clearbridge Invs Ltd Llc has 2.07 million shares for 0.07% of their US portfolio. Peak6 Invs Lp has 0.01% invested in the company for 34,134 shares. Alliancebernstein Lp last reported 99,711 shares in the company. California State Teachers Retirement accumulated 121,169 shares or 0.01% of the stock. Proshare Advsrs Limited Company owns 7,055 shares or 0% of their US portfolio. Arrowgrass Capital Prtn (Us) Limited Partnership last reported 148,538 shares in the company. Blackrock Institutional Tru Na accumulated 0.01% or 1.44M shares. New York State Common Retirement Fund, a New York-based fund reported 77,055 shares. The Minnesota-based Walleye Trading Limited Liability Co has invested 0% in Insulet Corporation (NASDAQ:PODD).

Insider Transactions: Since May 5, 2016, the stock had 3 buys, and 1 sale for $1.10 million net activity. $243,924 worth of Insulet Corporation (NASDAQ:PODD) shares were sold by SOMMER REGINA O. SULLIVAN PATRICK J had bought 45,000 shares worth $1.22 million on Tuesday, May 17. The insider Thomas Bradley A bought 2,975 shares worth $79,222.

More notable recent Insulet Corporation (NASDAQ:PODD) news were published by: which released: “Why Insulet Corporation Shares Are Soaring 19.5% Today” on August 04, 2016, also with their article: “Insulet Corporation to Announce Third Quarter 2016 Financial Results on …” published on September 27, 2016, published: “Why Insulet Corporation is Soaring Today” on February 26, 2016. More interesting news about Insulet Corporation (NASDAQ:PODD) were released by: and their article: “Insulet Corp.: Pumped Up!” published on September 21, 2016 as well as‘s news article titled: “Why Insulet Corporation and Tandem Diabetes Care Both Tanked Today” with publication date: May 03, 2016.

PODD Company Profile

Insulet Corporation, incorporated on July 20, 2000, is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Company’s principal offices are located in Billerica, Massachusetts. The OmniPod System features two discreet devices and provides for automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Firm is producing the OmniPod on semi-automated manufacturing lines at a facility in China, operated by a subsidiary of Flextronics International Ltd. (Flextronics). The Firm purchases OmniPods pursuant to its agreement with Flextronics. It also partners with pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. It sells the OmniPod System and other diabetes management supplies in the United States through direct sales to clients or through its distribution partners. The OmniPod System is available in multiple countries in Europe, Canada and Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment